HISTORICAL FACTS: Laurus labs - Caught on Camera

Indian markets snapped a five-session losing streak as easing Iran-US tensions, lower crude prices and upbeat earnings lifted sentiment. Sensex climbed 776 points and Nifty reclaimed 23,996, with analysts eyeing 24,250–24,300 if the index sustains above the 24,000 mark.

Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment.

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for…

Indian benchmark indices extended losses for a fourth straight session as FII selling and geopolitical concerns hurt sentiment. Amid the weakness, analysts recommend NMDC and Laurus Labs, citing bullish chart patterns, strong momentum, breakout formations and favorable technical indicators for further upside.

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business improvements, better margins, and strong earnings, the pharma major's market cap surged. Analysts see further upside but advise caution with stop losses due to the steep rise.

The drug manufacturer will also fund the clinical trials and launch the products in India and emerging markets. Additionally, it will establish a GMP (good manufacturing practice) facility at the Techno Park facility of IIT-K, Laurus said on Monday.